

## **NZX/ASX Announcement**

30 June 2025

### **TruScreen - Change of Special Meeting Date**

Truscreen Group Limited (NZX/ASX:TRU) advises that the Special Meeting of Shareholders scheduled for 11 July 2025 will now be held on 15 July 2025 at 11 am NZ Time.

The meeting will be held online only at:

[www.virtualmeeting.co.nz/trusm25](http://www.virtualmeeting.co.nz/trusm25)

This announcement has been approved by the Board.

### **Ends**

Guy Robertson  
Company Secretary  
Tel: +61 407 983 270  
Email: [guyrobertson@truscreen.com](mailto:guyrobertson@truscreen.com)

For more information, visit [www.truscreen.com](http://www.truscreen.com) or contact:

Mr Martin Dillon  
Chief Executive Officer  
[martindillon@truscreen.com](mailto:martindillon@truscreen.com)

Guy Robertson  
Chief Financial Officer  
[guyrobertson@truscreen.com](mailto:guyrobertson@truscreen.com)

## About TruScreen:

TruScreen Group Limited (NZX/ASX: TRU) is a medical device company that has developed and manufactures an AI-enabled device for detecting abnormalities in the cervical tissue in real-time via measurements of the low level of optical and electrical stimuli.

TruScreen's cervical screening technology enables cervical screening, negating sampling and processing of biological tissues, failed samples, missed follow-up, discomfort, and the need for costly, specialised personnel and supporting laboratory infrastructure.

The TruScreen device, TruScreen Ultra<sup>®</sup>, is typically registered as a primary screening device for cervical cancer screening.

The device is CE Marked/EC certified, ISO 13485 compliant and is registered for clinical use with the TGA (Australia), MHRA (UK), NMPA (China), SFDA (Saudi Arabia), Roszdravnadzor (Russia), and COFEPRIS (Mexico). It has Ministry of Health approval for use in Vietnam, Israel and the Philippines, among others and has distributors in over 20 countries. In 2021, TruScreen established a manufacturing facility in China for devices marketed and sold in China.

TruScreen technology has been recognised in CSCCP's (Chinese Society for Colposcopy and Cervical Pathology) China Cervical Cancer Screening Management Guideline.

TruScreen has been recognised in a China Blue Paper "Cervical Cancer Three Stage Standardized Prevent and Treatment" published on 28 April 2023.

In Dec 2023 TruScreen technology was added to the Vietnam Ministry of Health approved National Technical List, for use in Vietnam's public and private healthcare sectors and in 2024 was added to the Russian guidelines for the screening of cervical cancer.

In financial year 2025 alone, approximately 150,000<sup>1</sup> examinations were performed with the TruScreen device. To date, over 200 devices have been installed and used in China, Vietnam, Mexico, Zimbabwe, Russia, and Saudi Arabia. TruScreen's vision is "A world without the cervical cancer"<sup>®</sup>.

To learn more, please visit: [www.truscreen.com/](http://www.truscreen.com/).

<sup>1</sup>Based on Single Use Sensor sales.